Joanna Chataway

Inclusive innovation: an architecture for policy development

The past two decades have been characterized by an increasing uncoupling of economic growth and social and economic development. Outside of China, the numbers living in absolute poverty have remained stubbornly large; in Africa, they have increased substantially. Although this uncoupling has multiple sources, the trajectory of innovation (large in scale, capital intensive in nature and destructive of the environment) has contributed to these outcomes. Reorienting towards a more ‘inclusive innovation’ path has an important role to play in overcoming exclusion. However, we have only a weak understanding of the definition, nature and dynamics of inclusive innovation, and this paper seeks to fill this conceptual gap. It argues that inclusive innovation needs to be understood and developed in the context of a holistic conception of the innovation cycle, the distinction between process and product innovation and the roles played by the poor as both producers and consumer. It further charts the growing interest of private sector actors in inclusive innovation (including, but not confined to transnational corporations seeking the ‘fortune at the bottom of the pyramid’) and large global funds working in tandem with the private sector and governments. Consideration is also given to the role which growth trajectories play in determining the direction of innovation and in promoting linkages between the globally absolute poor (incomes below

Strategic integration of knowledge in Indian pharmaceutical firms: creating competencies for innovation

1pd) and those with discretionary cash incomes living in the margins above

The Governance of Agro- and Pharmaceutical Biotechnology Innovation: Public Policy and Industrial Strategy

1pd. The paper concludes with a call for a more holistic and balanced approach to inclusive innovation to be adopted by a range of stakeholders so that resources are deployed most effectively to aid the recoupling of growth and development.

Frameworks for pharmaceutical innovation in developing countries: the case of Indian pharma

Trade liberalisation and changes in the Intellectual Property Rights (IPR) have fashioned new dynamics in the pharmaceutical industry across the globe. Firms are forced to bring changes to their research, innovation, technology and marketing practices by a reconfiguration of their competencies and resources. The most common strategic concern that Trade Related Aspects of Intellectual Property Rights (TRIPs) has raised for Indian firms is the perceived need for R&D and technological strength. For firms that have given little attention to research and innovation in the past, this transition is very difficult. Indian firms have responded to these changes in novel and complex ways. Employing firm-level case studies, this paper examines the contemporary strategic approaches adopted by Indian leaders for integrating new knowledge and capabilities in order to develop innovation competencies for tomorrow. Using empirical evidence from firm-level investigations, this paper shows how Indian firms are evolving from reverse engineering outfits catering to domestic market to technologically advanced and sophisticated organisations capable of catering to diverse markets.

Knowledge Ecologies and Ecosystems? An Empirically Grounded Reflection on Recent Developments in Innovation Systems Theory

Abstract Multinational companies in the life science sector are heavily influenced by government policies and regulations and in turn attempt to influence these actors nationally and internationally. This paper focuses on recent and on-going research, principally on the agro-biotechnology and, to a lesser extent, on the pharmaceutical industries, covering the evolution of policy and regulation in Europe, how policies are influenced by stakeholder pressures and how policy in turn influences company strategies for product development. We focus particularly on new ‘governance’ agendas in Europe and consider the relative impacts of enabling, constraining, discriminating and indiscriminate policies on company strategies as part of our development of an integrated approach to policy and governance. We also consider changes in external operating environments for multinational companies and compare past histories and present pressures on agro-biotechnology and pharmaceutical companies. The paper argues, with evidence, that a more enabling and discriminating policy and regulatory environment can achieve public goals more efficiently and effectively, taking account of impacts on innovation, than more blunt policy instruments. This type of environment takes into account the resources and capabilities available to firms and research laboratories rather than relying on broad brush carrot and stick approaches.

Partnerships in African crop biotech.

Abstract Some industrially advanced developing countries have, in the last decades, built substantial pharmaceutical scientific and industrial capabilities. The more advanced of these countries have built chemical and biological R&D, generic and reverse engineering, and drug discovery capabilities. There have been tremendous barriers to entry but nevertheless a range of imitative approaches have evolved, with some significant scientific, health and industrial advances. Opportunities in India are in part created by the problems of maturity being faced by big pharmaceutical firms in developed countries. Big pharmaceutical firms are searching for novel approaches to retain a high value-added model of innovation for drug development. These difficulties provide opportunities for innovative companies in developing countries. This paper explores the challenges faced under these circumstances by Indian pharmaceutical companies. Are they attempting to ‘catch-up’ by chasing a failing model of innovation? Do they have an alternative model? Or can they become an important part of a transformed new global model of pharmaceutical innovation?

Policy, markets and knowledge: strategic synergies in Indian pharmaceutical firms

Recent academic and policy debate on innovation indicates that there has been some shift from a more traditional systems approach to ecologies and ecosystems. The latter are concepts transferred from the world of biology to the social world in order to explain the evolutionary nature of interrelations between different individuals, their innovative activities, and their environment. We evaluate the concept of knowledge ecology and the theory of innovation ecosystem on two fundamental grounds; firstly, on the grounds of theoretical plausibility and conceptual consistency; secondly, on empirical grounds of the case of public–private interrelations of biotech innovation in Cambridge. The argument is that the concept of knowledge ecology and the theory of innovation ecosystems can lead to problems of reductionism and functionalism. This is due to their development in abstraction from more grounded analysis of historical processes of the social division of labour. Knowledge and innovation need to be looked at in the context of historically founded processes of socioeconomic development.

Diffusion of knowledge through migration of scientific labour in India

Even in sub-Saharan Africas most progressive nations, agbiotech partnerships are still often poorly oriented to end users, fragmented in scope and of limited impact in achieving the United Nations Millennium Development Goals.

The governance of corporations, technological change, and risk: examining industrial perspectives on the development of genetically modified crops

Abstract This paper addresses the question of how Indian pharmaceutical firms have transformed themselves from reverse-engineering firms focused on the domestic market to research-driven firms with global presence. It analyses the crucial and changing role of national, then international, innovation and regulatory policies and their impact on growth, performance and technology evolution of Indian pharmaceutical firms. The paper argues that although public policy increased market turbulence, it also provided new opportunities for firms to expand and build new technology, knowledge and market capabilities. From the 1950s Indian firms have pursued a variety of research, marketing and internationalization strategies to tackle changes prompted by policy, markets and knowledge complexities. The paper traces firm strategies that vary both in time and by firm, and argues that the successful firms have evolved substantively towards knowledge-based strategies. The paper then attempts to identify future directions for strategy, knowledge and markets.

Management of agriculture-related biotechnology: constraints on innovation

‘Brain drain’ is viewed as a curse for developing countries but analysis suggests it may provide crucial advantage to some countries. ‘Reverse brain drain’ of engineers and scientists trained in the USA or Europe can accelerate technological catch-up. Communities of returned scientists and engineers can provide skill and know-how to help local firms shift to higher value-added activities. However, transfer of knowledge through human mobility is not a straightforward process. This paper presents insights regarding diffusion of knowledge through migration of scientific labour, using case studies of innovative Indian pharmaceutical firms. Copyright , Beech Tree Publishing.